CN116808224A - 用于治疗血管疾病的化合物组合 - Google Patents

用于治疗血管疾病的化合物组合 Download PDF

Info

Publication number
CN116808224A
CN116808224A CN202310100652.1A CN202310100652A CN116808224A CN 116808224 A CN116808224 A CN 116808224A CN 202310100652 A CN202310100652 A CN 202310100652A CN 116808224 A CN116808224 A CN 116808224A
Authority
CN
China
Prior art keywords
sildenafil
arginine
acetylcysteine
vascular
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310100652.1A
Other languages
English (en)
Chinese (zh)
Inventor
招名威
林钦鸿
陈伯东
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhao Xianbang
Future New Drug Co ltd
Original Assignee
Zhao Xianbang
Future New Drug Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhao Xianbang, Future New Drug Co ltd filed Critical Zhao Xianbang
Publication of CN116808224A publication Critical patent/CN116808224A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202310100652.1A 2022-02-09 2023-02-09 用于治疗血管疾病的化合物组合 Pending CN116808224A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TW111104639A TWI859506B (zh) 2022-02-09 2022-02-09 化合物組合用於製作血管疾病治療藥的用途
TW111104639 2022-02-09

Publications (1)

Publication Number Publication Date
CN116808224A true CN116808224A (zh) 2023-09-29

Family

ID=85283927

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202310100652.1A Pending CN116808224A (zh) 2022-02-09 2023-02-09 用于治疗血管疾病的化合物组合

Country Status (8)

Country Link
US (1) US20250134892A1 (cg-RX-API-DMAC10.html)
EP (1) EP4475833A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025504219A (cg-RX-API-DMAC10.html)
KR (1) KR20240146018A (cg-RX-API-DMAC10.html)
CN (1) CN116808224A (cg-RX-API-DMAC10.html)
AU (1) AU2023219232A1 (cg-RX-API-DMAC10.html)
TW (1) TWI859506B (cg-RX-API-DMAC10.html)
WO (1) WO2023152500A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI879058B (zh) * 2023-08-31 2025-04-01 未來新藥股份有限公司 Pde5抑制劑組合於促進神經突生長之新穎用途
CN122055146A (zh) * 2023-08-31 2026-05-15 未来新药股份有限公司 Pde5抑制剂组合于促进神经突生长的新颖用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4699299A (en) 1998-06-26 2000-01-17 Nutracorp Scientific, Inc. Promoting nitric oxide and cyclic gmp activity
IL132460A0 (en) * 1999-10-19 2001-03-19 Laniado Shlomo Sildenafil preparation

Also Published As

Publication number Publication date
US20250134892A1 (en) 2025-05-01
TW202332450A (zh) 2023-08-16
EP4475833A1 (en) 2024-12-18
KR20240146018A (ko) 2024-10-07
WO2023152500A1 (en) 2023-08-17
AU2023219232A1 (en) 2024-07-25
JP2025504219A (ja) 2025-02-06
TWI859506B (zh) 2024-10-21

Similar Documents

Publication Publication Date Title
US6245789B1 (en) HIV and viral treatment
RU2440127C2 (ru) Лекарственные формы, полезные для лечения мужской и женской импотенции
US7438934B2 (en) Formulations useful in the treatment of male and female impotence
KR100849999B1 (ko) 두통, 편두통, 구역질 및 구토를 위한 약학적 조성물
CA2285394A1 (en) Antimicrobial prevention and treatment of human immunedeficiency virus and other infectious diseases
US20250134892A1 (en) Combination of compounds for treating vascular diseases comprising pde5 inhibitor, arginine and n-acetylcysteine
ES2987802T3 (es) Uso de comprimidos bucodispersables de riluzol para el tratamiento de enfermedades
LT3119B (en) Pharmaceutical composition and process for the preparation thereof
WO2013081154A1 (ja) キナーゼ阻害剤の副作用低減剤
KR101516677B1 (ko) 지방성 간 질환의 치료용 의약 조성물
JP2014527506A (ja) 糖尿病治療のための組み合わせ
US20200069758A1 (en) Composition for use in the preventive and/or curative treatment of non-alcoholic fatty liver disease
JP2014221735A (ja) ショウガオール類を有効成分として含有する肝細胞活性化剤、並びに該肝細胞活性化剤を含有する固形製剤、液状製剤及び機能性食品
WO2021201169A1 (ja) 男性不妊症における精子所見を改善するための経口摂取用組成物
WO2025026900A1 (en) Compounds for the treatment or prevention of gout
JP5883687B2 (ja) Pde5阻害剤含有医薬組成物
US20210128596A1 (en) Compositions and methods for treating septic cardiomyopathy
RU2250768C2 (ru) Фармацевтическая композиция и способ лечения прогрессирующего фиброза и цирроза печени
US20250009692A1 (en) Micronutrient composition to prevent and reverse protein glycation during oxidative stress in human
US20060194810A1 (en) Methods of treating ischemic related conditions
TWI879058B (zh) Pde5抑制劑組合於促進神經突生長之新穎用途
WO2022005848A1 (en) Combinations of carnosine and zinc for the treatment and prevention of viral infections
Imperial Effect of Aspalathus linearis supplementation, during anti-retroviral treatment, on the heart and aortas of male Wistar rats and the effects of drinking rooibos on the cardiovascular profile of patients on ART.
JPH10279497A (ja) β−アミノ酸吸収抑制剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination